JP7432516B2 - ブタトリプシンの変異体 - Google Patents

ブタトリプシンの変異体 Download PDF

Info

Publication number
JP7432516B2
JP7432516B2 JP2020544428A JP2020544428A JP7432516B2 JP 7432516 B2 JP7432516 B2 JP 7432516B2 JP 2020544428 A JP2020544428 A JP 2020544428A JP 2020544428 A JP2020544428 A JP 2020544428A JP 7432516 B2 JP7432516 B2 JP 7432516B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
insulin
arg
trypsin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020544428A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514194A (ja
Inventor
トーマス・シュティルガー
セバスティアン・リソム
クラウディア・フェラー
アンドレアス・フォーゲル
Original Assignee
サノフィ－アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サノフィ－アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング filed Critical サノフィ－アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Publication of JP2021514194A publication Critical patent/JP2021514194A/ja
Priority to JP2023220226A priority Critical patent/JP7699196B2/ja
Application granted granted Critical
Publication of JP7432516B2 publication Critical patent/JP7432516B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21004—Trypsin (3.4.21.4)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
JP2020544428A 2018-02-22 2019-02-22 ブタトリプシンの変異体 Active JP7432516B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023220226A JP7699196B2 (ja) 2018-02-22 2023-12-27 ブタトリプシンの変異体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18158034 2018-02-22
EP18158034.1 2018-02-22
PCT/EP2019/054400 WO2019162423A1 (en) 2018-02-22 2019-02-22 Variants of porcine trypsin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023220226A Division JP7699196B2 (ja) 2018-02-22 2023-12-27 ブタトリプシンの変異体

Publications (2)

Publication Number Publication Date
JP2021514194A JP2021514194A (ja) 2021-06-10
JP7432516B2 true JP7432516B2 (ja) 2024-02-16

Family

ID=61274085

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020544428A Active JP7432516B2 (ja) 2018-02-22 2019-02-22 ブタトリプシンの変異体
JP2023220226A Active JP7699196B2 (ja) 2018-02-22 2023-12-27 ブタトリプシンの変異体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023220226A Active JP7699196B2 (ja) 2018-02-22 2023-12-27 ブタトリプシンの変異体

Country Status (13)

Country Link
US (2) US11518988B2 (enExample)
EP (1) EP3755794A1 (enExample)
JP (2) JP7432516B2 (enExample)
KR (1) KR102863070B1 (enExample)
CN (1) CN111989401A (enExample)
AU (1) AU2019225972B2 (enExample)
BR (1) BR112020016954A2 (enExample)
CA (1) CA3091943A1 (enExample)
IL (1) IL276799A (enExample)
MX (1) MX2020008766A (enExample)
MY (1) MY200951A (enExample)
SG (1) SG11202008026WA (enExample)
WO (1) WO2019162423A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024038140A (ja) * 2018-02-22 2024-03-19 サノフィ－アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ブタトリプシンの変異体

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111676211B (zh) * 2020-05-15 2022-07-19 天津科技大学 一种抗自切和高比活力胰蛋白酶突变体
CN119552847B (zh) * 2025-01-21 2025-04-11 四川大学 链霉菌胰蛋白酶自剪切位点突变体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009507500A (ja) 2005-09-14 2009-02-26 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング トリプシンの変異体によるインスリン前駆体の切断

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010022452A (ko) * 1997-07-31 2001-03-15 추후제출 플라비바이러스 감염에 대한 재조합 다이머형 엔벨롭 백신
US7622113B2 (en) * 2003-12-08 2009-11-24 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus
BR112013009649A2 (pt) * 2010-10-29 2016-07-12 Merck Sharp & Dohme composição imunogênica, métodos para provocar uma resposta imune protetora em um paciente humano e para fornecer proteção imune em seres humanos contra doença, e, uso de uma composição
US9267114B2 (en) * 2012-11-07 2016-02-23 Southern Research Institute Flavivirus envelope protein mutations affecting virion disassembly
WO2019162423A1 (en) * 2018-02-22 2019-08-29 Sanofi-Aventis Deutschland Gmbh Variants of porcine trypsin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009507500A (ja) 2005-09-14 2009-02-26 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング トリプシンの変異体によるインスリン前駆体の切断

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
cationic trypsinogen[Rattus norvegicus]，GenBank Accession No.EDM15437.1，2016年07月26日，[2023年2月28日検索]インターネット

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024038140A (ja) * 2018-02-22 2024-03-19 サノフィ－アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ブタトリプシンの変異体

Also Published As

Publication number Publication date
RU2020130880A (ru) 2022-03-22
CA3091943A1 (en) 2019-08-29
US11952602B2 (en) 2024-04-09
BR112020016954A2 (pt) 2020-12-29
JP7699196B2 (ja) 2025-06-26
MX2020008766A (es) 2020-12-07
KR20200124255A (ko) 2020-11-02
US20200377873A1 (en) 2020-12-03
RU2020130880A3 (enExample) 2022-03-22
NZ768123A (en) 2026-02-27
SG11202008026WA (en) 2020-09-29
JP2021514194A (ja) 2021-06-10
KR102863070B1 (ko) 2025-09-22
AU2019225972A1 (en) 2020-10-15
JP2024038140A (ja) 2024-03-19
US20230303994A1 (en) 2023-09-28
AU2019225972B2 (en) 2024-10-17
WO2019162423A1 (en) 2019-08-29
MY200951A (en) 2024-01-25
CN111989401A (zh) 2020-11-24
EP3755794A1 (en) 2020-12-30
IL276799A (en) 2020-10-29
US11518988B2 (en) 2022-12-06

Similar Documents

Publication Publication Date Title
JP7699196B2 (ja) ブタトリプシンの変異体
US10898545B2 (en) Tear lipocalin muteins binding IL-4 r alpha
JP4344136B2 (ja) アポリポタンパク質類似体
AU2007291501B2 (en) Method for the production of insulin-like growth factor-I
JP2016519051A (ja) 新規のｐｃｓｋ９結合タンパク質
KR20230017804A (ko) Rhfgf21 융합 단백질, rhfgf21 융합 단백질을 인코딩하는 폴리뉴클레오티드, rhfgf21 융합 단백질을 포함하는 조성물, 및 rhfgf21 융합 단백질의 용도
EP4471138A1 (en) Iga protease truncation, fusion protein comprising iga protease truncation, and use thereof
RU2584572C2 (ru) Способ получения полипептида, конъюгированного с поли(этиленгликолевым) фрагментом, нуклеиновая кислота и слитый полипептид, предназначенные для применения в способе
KR101634078B1 (ko) 봉입체 형성 단백질의 제조방법
CN118302523B (zh) 包含IgA蛋白酶截短体的融合蛋白及其用途
RU2783315C2 (ru) Варианты свиного трипсина
CN119546286A (zh) Klk1融合蛋白的制备方法
EA052996B1 (ru) Усеченные формы iga-протеазы, слитые белки, содержащие усеченную форму iga-протеазы, и их применение
HK40111214A (en) Fusion protein containing truncated iga protease and use thereof
HK40111214B (en) Fusion protein containing truncated iga protease and use thereof
CA3297420A1 (en) Preparation method for klk1 fusion protein
Sriveny et al. Expression of recombinant fatty acid binding protein from Fasciola gigantica

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230607

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231227

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240123

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240205

R150 Certificate of patent or registration of utility model

Ref document number: 7432516

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150